The evolution of the use of faecal microbiota transplantation and emerging therapeutic indications
Jessica R Allegretti, Benjamin H Mullish, Colleen Kelly, Monika Fischer, Jessica R Allegretti, Benjamin H Mullish, Colleen Kelly, Monika Fischer
Abstract
Developments in high-throughput microbial genomic sequencing and other systems biology techniques have given novel insight into the potential contribution of the gut microbiota to health and disease. As a result, an increasing number of diseases have been characterised by distinctive changes in the composition and functionality of the gut microbiota; however, whether such changes are cause, consequence, or incidental to the disease in question remains largely uncertain. Restoration of the gut microbiota to a premorbid state is a key novel therapeutic approach of interest, and faecal microbiota transplantation-the transfer of prescreened stool from healthy donors into the gastrointestinal tract of patients-is gaining increasing importance in both the clinical and research settings. At present, faecal microbiota transplantation is only recommended in the treatment of recurrent Clostridioides difficile infection, although a large number of trials are ongoing worldwide exploring other potential therapeutic indications.
Copyright © 2019 Elsevier Ltd. All rights reserved.
Source: PubMed